These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35044835)

  • 1. Clinical application of serum tumor abnormal protein combined with tumor markers in lung cancer patients.
    Tong H; Dan B; Dai H; Zhu M
    Future Oncol; 2022 Apr; 18(11):1357-1369. PubMed ID: 35044835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Beinert T; Fürst H; Fink U
    Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
    Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
    Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of serum tumor markers in patients with lung cancer.
    Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
    Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer.
    Wang P; Piao Y; Zhang X; Li W; Hao X
    Cancer Biomark; 2013; 13(2):123-30. PubMed ID: 23838141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
    Lee JH; Chang JH
    Chest; 2005 Oct; 128(4):2298-303. PubMed ID: 16236887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U
    Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
    Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
    Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
    Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
    Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
    Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic value of the combination of carcinoembryonic antigen, squamous cell carcinoma-related antigen, CYFRA 21-1, neuron-specific enolase, tissue polypeptide antigen, and progastrin-releasing peptide in small cell lung cancer discrimination.
    Chen Z; Liu X; Shang X; Qi K; Zhang S
    Int J Biol Markers; 2021 Dec; 36(4):36-44. PubMed ID: 34709098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of serum CYFRA 21-1 in lung cancer.
    Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
    Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical role of serum tumor markers SCC, NSE, CA 125, CA 19-9, and CYFRA 21-1 in patients with lung cancer.
    Sun A
    Lab Med; 2023 Nov; 54(6):638-645. PubMed ID: 37052517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer.
    Cabrera-Alarcon JL; Carrillo-Vico A; Santotoribio JD; Leon-Justel A; Sanchez-Gil R; Gonzalez-Castro A; Guerrero JM
    Clin Lab; 2011; 57(11-12):1011-4. PubMed ID: 22239035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoassay of neuron-specific enolase (NSE) and serum fragments of cytokeratin 19 (CYFRA 21.1) as tumor markers in small cell lung cancer: clinical evaluation and biological hypothesis.
    Giovanella L; Piantanida R; Ceriani L; Bandera M; Novario R; Bianchi L; Roncari G
    Int J Biol Markers; 1997; 12(1):22-6. PubMed ID: 9176714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
    Trulson I; Klawonn F; von Pawel J; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.